GLP-1 receptor agonists such as semaglutide and tirzepatide are FDA-regulated for chronic weight management in adults with a BMI of 30 or higher, or 27 with a weight-related condition. Las Vegas runs around the clock, and dealers, servers, performers and resort staff working overnight and rotating shifts rarely fit a daytime clinic into their week - even as the job keeps appearance and stamina front of mind. Telehealth works on their clock: a licensed Nevada physician reviews your online assessment under Nevada Revised Statutes §629.515, and compounded medication from an FDA-registered 503B pharmacy ships to your Las Vegas address. Monthly cost runs $199–$379 versus about $1,247 for brand-name Ozempic or Wegovy. Medical Director: Dr. Steven Nguyen, MD, Board-Certified Internal Medicine. Serving Las Vegas ZIP codes: 89101, 89102, 89104, 89109, 89119.
Local clinics serving Henderson 89014: Nevada Weight Loss Wellness. Many patients compare these in-person options against licensed GLP-1 telehealth — prescribed online, shipped to the door.
Tirzepatide seen from Henderson 89014, without the jargon. Tirzepatide is the newest and most potent molecule in the incretin class: it is the first approved dual GIP/GLP-1 agonist, often chosen when semaglutide plateaus.
Pregnancy and breastfeeding are among the situations where these treatments are not indicated. Beyond the numbers, the evaluation factors in your history, current medications, and contraindications specific to the molecule.
With a local obesity rate around 30.6% and 11.0% uninsured, demand for Tirzepatide runs high around Henderson 89014. Around Henderson 89014 in Clark County, 1 weight-management practice(s) are listed locally. In this state, Nevada Revised Statutes §629.515; the reference body is Nevada State Board of Medical Examiners. Associated brands include Mounjaro, Zepbound.
Yes: both are tirzepatide. Mounjaro is dosed/labeled for type 2 diabetes, Zepbound for weight management.
Often a BMI of 30 or higher, or 27 or higher with a weight-related comorbidity, but only the medical evaluation decides.
In the SURMOUNT head-to-head trials, tirzepatide produced greater average weight loss, likely thanks to its dual GIP + GLP-1 action. Response is individual and should be assessed by a physician.
Medical Director: Dr. Steven Nguyen, MD, Board-Certified Internal Medicine. Licensed in Nevada. All prescriptions issued under Nevada Revised Statutes §629.515 and supervised by Nevada State Board of Medical Examiners.